The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. ANI Pharmaceuticals (ANIP) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? Let's take a closer look at the stock's year-to-date performance to find out.
ANI Pharmaceuticals is a member of the Medical sector. This group includes 947 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. ANI Pharmaceuticals is currently sporting a Zacks Rank of #1 (Strong Buy).
The Zacks Consensus Estimate for ANIP's full-year earnings has moved 5.5% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, ANIP has gained about 52.6% so far this year. Meanwhile, the Medical sector has returned an average of 8.8% on a year-to-date basis. This means that ANI Pharmaceuticals is performing better than its sector in terms of year-to-date returns.
Another Medical stock, which has outperformed the sector so far this year, is Black Diamond (BDTX). The stock has returned 76.6% year-to-date.
In Black Diamond's case, the consensus EPS estimate for the current year increased 33.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, ANI Pharmaceuticals is a member of the Medical - Biomedical and Genetics industry, which includes 467 individual companies and currently sits at #90 in the Zacks Industry Rank. Stocks in this group have gained about 20.4% so far this year, so ANIP is performing better this group in terms of year-to-date returns. Black Diamond is also part of the same industry.
Going forward, investors interested in Medical stocks should continue to pay close attention to ANI Pharmaceuticals and Black Diamond as they could maintain their solid performance.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
ANI Pharmaceuticals, Inc. (ANIP): Free Stock Analysis Report Black Diamond Therapeutics, Inc. (BDTX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
